ArticleMolecular neurobiology2025
Salidroside-Pretreated Small Extracellular Vesicles Derived from Human Umbilical Cord Mesenchymal Stem Cells Promote Blood-Spinal Cord Barrier Repair After Spinal Cord Injury in Mice.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Current status and future prospects of functionalized mesenchymal stem cells for the treatment of spinal cord injury.Journal of orthopaedic translation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates the role of salidroside-pretreated small extracellular vesicles (SAL-sEVs) derived from human umbilical cord mesenchymal stem cells (Huc-MSCs) in spinal cord injury (SCI). Results demonstrate that these sEVs repair the damaged blood-spinal cord barrier (BSCB) and facilitate functional recovery. sEVs were collected from Huc-MSCs pretreated with salidroside via ultracentrifugation. sEVs were characterized using transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA), and Western blot. The uptake of sEVs by endothelial cells was confirmed through immunofluorescence. The regulatory effects of SAL-sEVs on BSCB permeability and tight junction proteins were examined using immunofluorescence and Western blot. Microglial polarization was assessed via ELISA, qRT-PCR, and Western blot. Motor function was evaluated through behavioral tests. SAL-sEVs were endocytosed by endothelial cells, reduced BSCB permeability by regulating tight junction proteins, alleviated secondary inflammation, facilitated repair of spinal cord injury sites, and improved motor function in mice. Salidroside augments the therapeutic promise of Huc-MSC-derived small extracellular vesicles in repairing the BSCB, inflammation reduction, and functional recovery post-SCI, offering a novel therapeutic approach for the treatment of SCI.
Indexed as
Identifiers
41261280What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.